693793-53-2

Usage

Uses

Used in Pharmaceutical Industry:
Atorvastatin Related Compound C (20 mg) (Difluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt) is used as an impurity reference standard for the development, manufacturing, and quality control of Atorvastatin and its formulations. It helps in ensuring the safety, efficacy, and quality of Atorvastatin drugs by providing a reference for the identification, quantification, and control of impurities during the drug development process.
Used in Research and Development:
In the field of research and development, Atorvastatin Related Compound C (20 mg) (Difluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt) serves as a valuable tool for studying the structure-activity relationship, pharmacokinetics, and pharmacodynamics of Atorvastatin and its analogs. Atorvastatin Related Compound C (20 mg) (Difluoro impurity,
or (3R,5R)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-
2-isopropyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
calcium salt) can be used to investigate the effects of structural modifications on the biological activity, safety, and efficacy of Atorvastatin, leading to the development of new and improved cholesterol-lowering drugs.
Used in Quality Control and Regulatory Compliance:
Atorvastatin Related Compound C (20 mg) (Difluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-4,5-bis(4-fluorophenyl)-2-isopropyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt) is utilized in the quality control and regulatory compliance of Atorvastatin drug products. It is essential for the development and validation of analytical methods, such as high-performance liquid chromatography (HPLC) and mass spectrometry, to accurately detect and quantify impurities in Atorvastatin formulations. This ensures that the drug products meet the required quality standards and regulatory guidelines, ultimately safeguarding patient health.